MOCI : [25] Collection home page

Browse
in this collection
Subscribe to this collection to receive daily e-mail notification of new additions RSS Feed RSS Feed RSS Feed
Collection's Items (Sorted by Submit Date in Descending order): 1 to 20 of 25
Issue DateTitleAuthor(s)
2019-07The use of optimal treatment for DLBCL is improving in all age groups and is a key factor in overall survival, but non-clinical factors influence treatment.Prince, Miles; Doo, Nicole; White, Victoria; Martin, Kara; Bassett, Julie; Harrison, Simon; Jefford, Michael; Winship, Ingrid; Millar, Jeremy; Milne, Roger; Seymour, John; Giles, Graham 
2020-12A phase I study to evaluate the safety and pharmacokinetic profiles of CB-5339 in participants with relapsed/refractory acute myeloid leukemia or relapsed/refractory intermediate or high-risk myelodysplastic syndrome.Yannakou, Costas; Benajiba, Lena; Caraway, Hetty; Hamad, Nada; Stein, Eytan; Burroughs, Amy; Haris, Scott; Lane, Hayley; Ngyuen, Dorothy; Stuart, Monic; Vargas, Jesse; Puissant, Alexandre; Stegmaier, Kimberly; Dinardo, Courtney 
2020-06A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History.Yellapu, Bhargavi; Prall, Owen; McEvoy, Christopher; Byrne, David; Iravani, Amir; Browning, Judy; Yew, David; O'Haire, Sophie; Smith, Kortnye; Luen, Stephen; Mitchell, Paul; Desai, Jayesh; Fox, Stephen; Fellowes, Andrew; Xu, Huiling 
2020-11A novel application of [18F] fluorothymidine-PET ([18F]FLT-PET) in clinical practice to quantify regional bone marrow function in a patient with treatment-Induced cytopenias and to guide "marrow-sparing" radiotherapy.Prince, Miles; Campbell, Belinda; Hofman, Michael 
2020-02A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.Prince, Miles; Maqbool, M. Gohar; Tam, Constantine; Morison, Ian; Simpson, David; Mollee, Peter; Schneider, Hans; Chan, Henry; Juneja, Surrender; Harvey, Yasmin; Nath, Lakshmi; Hissaria, Pravin; Wordsworth, Helen; Opat, Stephen; Talaulikar, Dipti 
2020-12707 Survival outcomes for plasmablastic lymphoma: an international, multicentre study by the Australasian Lymphoma Alliance.Yannakou, Costas; Polizzotto, Mark; Cwynarski, Kate; Burton, Cathy; Jiamsakul, Awachana; Bower, Mark; Kuruvilla, John; Montoto, Silvia; McKay, Pam; Osborne, Wendy; Miliken, Sam; Linton, Kim; Manos, Kate; Kassam, Shireen; Doo, Nicole; Watson, Anne-Marie; Fedele, Pasquale; Hunt, Stewart; Renshaw, Hanna; Thakrar, Nisha; Smith, Alexandra; Painter, Daniel; Maxwell, Alice; Liu, Qin; Dhairyawan, Rageshri; Ferguson, Graeme; Pickard, Keir; Hamad, Nada 
2020-07Prolonged lymphopenia and infection risk is mitigated by antimicrobial prophylaxis in patients with indolent non-Hodgkin Lymphoma (iNHL) treated with bendamustine +/- anti-CD20 antibody: the Australian Lymphoma Alliance experience.Yannakou, Costas; Manos, Kate; Lasica, Masa; Grigg, Andrew; Di Ciaccio, Pietro; Wong, Jonathan; Sekaran, Usha; Wight, Joel; Goh, Zhong; Jina, Hayden; Butler, Llewyn; Hamad, Nada; Gregory, Gareth; Gangatharan, Shane; Cochrane, Tara; Piper, Kristen; Churilov, Leonid; Hawkes, Eliza 
2020-10Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukaemia and follicular lymphoma.Prince, Miles; Tam, Constantine; Quach, Hang; Nicol, Andrew; Badoux, Xavier; Rose, Hannah; Leahy, Michael; Wickham, Nicholas; Patil, Sushrut; Huang, Jane; Prathikanti, Radha; Cohen, Aileen; Elstrom, Rebecca; Reed, William; Schneider, Jingjing; Flinn, Ian 
2020-10T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.Prince, Miles; Ghione, Paola; Faruque, Promie; Mehta-Shah, Neha; Seshan, Venkatraman; Ozkaya, Neval; Bhaskar, Shakthi; Yeung, James; Spinner, Michael; Lunning, Matthew; Inghirami, Giorgio; Moskowitz, Alison; Galasso, Natasha; Ganesan, Nivetha; van der Weyden, Carrie; Ruan, Jia; Trotmani, Judith; Advani, Ranjana; Dogan, Ahmet; Horwitz, Steven 
2020-05Safety and activity of the once daily selective Bruton Tyrosine Kinase (BTK) inhibitor TG-1701 in patients with chronic lymphocytic leukaemia (CLL) and lymphoma.Yannakou, Costas; Chan, Cheah; Wickham, Nicholas; Lewis, Katharine; Hui, Chi-Hung; Tang, Pek; Turpuseema, Tejasvi; Miskin, Hari; Tang, Jian-Ping; Normant, Emmanuel; Ricart, Alejandro; Tam, Constantine 
2020-11Survival outcomes for plasmablastic lymphoma: an international, multicentre study by the Australasian Lymphoma Alliance.Yannakou, Costas; Di Ciaccio, Pietro; Polizzotto, Mark; Cwynarski, Kate; Burton, Cathy; Jiamsakul, Awachana; Bower, Mark; Kuruvilla, John; Montoto, Silvia; McKay, Pam; Osborne, Wendy; Milliken, Sam; Linton, Kim; Manos, Kate; Kassam, Shireen; Doo, Nicole; Watson, Ann-Marie; Fedele, Pasquale; Hunt, Stewart; Renshaw, Hanna; Thakrar, Nisha; Smith, Alexandra; Painter, Daniel; Maxwell, Alice; Liu, Qin; Dhairyawan, Rageshri; Ferguson, Graeme; Pickard, Keir; Hamad, Nada 
2019-08Characterisation of the immune evasion phenotype of Richter Syndrome and the implications for immune checkpoint therapy.Yannakou, Costas; Gould, Clare; Lickiss, Jennifer; Kankanige, Yamuna; Yerneni, Satwica; Markham, John; Villa, Diego; Slack, Graham; Chin, Collin; Tam, Constantine; Lade, Stephen; Nelson, Niles; Neeson, Paul; Seymour, John; Dickinson, Michael; Westerman, David; Blombery, Piers 
2020-07Clinical activity of TG-1701, as monotherapy and in combination with Ublituximab and Umbralisib (U2), in patients with B-cell malignancies.Yannakou, Costas; Chan, Cheah; Wickham, Nick; Jurczak, Wojciech; Lasica, Masa; Wrobel, Tomasz; Lewis, Katharine; Długosz-Danecka, Monika; Giannopoulos, Krzysztof; Miskin, Hari; Tang, Jian-Ping; Normant, Emmanuel; Ricart, Alejandro; O'Connor, Owen; Tam, Constantine 
2020-10Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70)is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studiesPrince, Miles H.; Leleu, Xavier; Beksac, Meral; Chou, Takaaki; Dimopoulos, Meletios; Yoon, Sung-Soo; Pour, Ludek; Shelekhova, Tatiana; Chari, Ajai; Khurana, Monica; Zhang, Jianqi; Obreja, Mihaela; Qi, Ming; Oriol, Albert; Siegel, David 
2020-10Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma.Yannakou, Costas; Prince, Miles; Abeyakoon, Chathuri; van der Weyden, Carrie; Harrop, Sean; Khot, Amit 
2020-11CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma.Yannakou, Costas; Khodadoust, Michael; Feldman, Tatyana; Yoon, Dok; Radeski, Dejan; Kim, Youn; Mehta Shah, Meta; Khot, Amit; Wilcox, Ryan; King, Won; Horwitz, Steven; Buggy, Joseph; Hotson, Andrew; Hill, Craig; Munneke, Brian; Mahabhashyam, Suresh; Miller, Richard; Janc, James; Mobasher, Merhdad 
2021TG-1701, A selective Bruton Tyrosine Kinase (BTK) Inhibitor, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients with B- Cell Malignancies.Yannakou, Costas; Chan, Cheah; Wojciech, Jurczak; Lasica, Masa; Wickham, Nicholas; Wrobel, Tomasz; Andrzej, Jan; Cheung, Stanley; Lewis, Katharine; Długosz-Danecka, Monika; Giannopoulos, Krzysztof; Miskin, Hari; Tan, Jian-Ping; Normant, Emmanuel; O'Connor, Owen; Ricart, Alejandro; Tam, Constantine 
2021-06First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).Yannakou, Costas; Prince, Miles; Ailawadhi, Sikander; Chanan-Khan, Asher Alban Akmal; Chen, Zi; Huang, Bo; Konopleva, Marina; Brander, Danielle; Rizzieri, David; Lasica, Masa; Tam, Constantine Si Lun; Davids, Matthew; He, Zhicong; Lu, Ming; Ahmad, Mohammad; Li, Mingyu; Liang, Zhiyan; Mudenda, Boyd; Yang, Dajun; Zhai, Yifan 
2021-05Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies.Yannakou, Costas; Cheah, Chan; Jurczak, Wojciech; Lasica, Masa; Wickham, Nicholas W.; Wrobel, Tomasz; Andrzej Walewski,, Jan; Cheung, Stanley; Lewis, Katharine L.; Długosz-Danecka, Monika; Giannopoulos, Krzysztof; Miskin, Hari P.; Tang, Jian-Ping; Normant, Emmanuel; O'Connor, Owen A.; Ricart, Alejandro Daniel; Tam, Constantine Si Lun 
2021-05Management of hydroxyurea resistant or intolerant polycythemia vera.Prince, Miles; Raman, Indu; Yannakou, Costas; Pasricha, Sant-Rayn 
Collection's Items (Sorted by Submit Date in Descending order): 1 to 20 of 25